Wednesday
18:45 - 20:15
Carrasco Hall

Improving CV risk in patients with obesity

Evening Session

Lars Rydén (Sweden)
Welcome and introduction
John Wilding (UK)
Does weight loss affect CV risk?
Ben Scirica (USA)
What do we know from CVOTs in obesity?
Lars Rydén (Sweden)
The major threat of our time: the global interrelation between obesity, T2D and CVD
Lars Rydén (Sweden), John Wilding (UK), Ben Scirica (USA)
Panel discussion and meeting close

Disclaimer: Oral Semaglutide has been studied in a phase 3 clinical trial programme

Symposia by: